BioCardia BCDA 深 滬
等待開盤 07-30 09:30:00 美东时间
0.7862
+0.005
+0.60%
華盛通- 最 高0.8248
- 今 開0.79
- 成交量 7.29万股
- 最 低 0.778
- 昨 收 0.7815
- 總市值 1170.21万
- 52周最高 2.29
- 市盈率 靜 --
- 換手率 0.49%
- 52周最低 0.75
- 委 比 99.60%
- 總股本 1488.43万
- 歷史最高 129.00
- 量 比 0.60
- 振 幅 5.99%
- 歷史最低 0.75
- 每 手 1
- 風險率 0.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股夜盘 | Pineapple Financial Inc.涨34.47%，Advanced Biomed涨18.88%
Eva Live Inc涨-12.29%；Globavend Holdings涨-10.81%；BioCardia涨-5.70%
07-21 08:05
BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities
BioCardia Inc., a global leader in cellular and cell-derived therapeutics, announced its strategic priorities and business developments. The company is focusing on seeking regulatory approval for its CardiAMP® Cell Therapy in Japan for ischemic heart failure, targeting 20,000 patients initially. Japan's status as a trusted Reference Country and MDSAP member could streamline approvals in other regions. BioCardia is also advancing the CardiAMP HF I...
06-18 12:00
美股大行评级 | 潜在涨幅321.55%！Shattuck Labs获花旗升目标价至18美元，维持"买入"评级
今日重点评级关注：花旗：维持Shattuck Labs"买入"评级，目标价从7美元升至18美元；Benchmark：维持Gloo Holdings"买入"评级，目标价从14美元升至15美元
06-10 12:32
Why Is BioCardia Stock Gaining Friday?
BioCardia stock breaks above its 200-day moving average on huge FDA news. Can BCDA clear the $1.50 resistance? Get the technical outlook.
06-05 23:06
BioCardia Receives FDA Confirmation For Its Biologics Evaluation And Research On CardiAMP Cell Therapy System To Treat Ischemic Heart Failure Of Reduced Ejection Fraction
BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced receipt of FDA minutes from its Q-Sub Meeting
06-05 20:03
FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF
BioCardia announced FDA meeting minutes supporting potential Premarket Approval (PMA) for its CardiAMP Cell Therapy System to treat ischemic heart failure with reduced ejection fraction (HFrEF). The ongoing CardiAMP Heart Failure II Trial may provide sufficient evidence for PMA, the most rigorous device marketing application. FDA previously acknowledged the therapy's safety, enabling Medicare and Medicaid reimbursement. BioCardia aims to publish ...
06-05 12:00
BioCardia Announces Presentation Of Data From CardiAMP Minimally-Invasive Chronic Myocardial Ischemia Treatment Trial Demonstrating Positive Clinical Outcomes
Results presented by Dr. Raval, on behalf of the CardiAMP CMI Investigators, showed that the minimally invasive CardiAMP Cell Therapy procedure was well tolerated with no treatment emergent major adverse cardiac events
05-21 20:04
BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency
BioCardia's CardiAMP Cell Therapy trial shows positive results for patients with severe refractory angina, demonstrating improved exercise tolerance and reduced angina episodes. The minimally invasive procedure was well-tolerated with no major adverse events. Patients experienced a 179-second increase in exercise capacity and an 82% reduction in angina episodes within six months. This novel cell therapy addresses an unmet need for patients who ha...
05-21 12:00
电话会总结 ｜ BioCardia(BCDA)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据BioCardia业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩：- **净亏损**：2026年第一季度净亏损230万美元，较2025年同期的270万美元减少40万美元 - **总费用**：2026年第一季度总费用230万美元，较上一季度减少46万美元 - **运营现金流**：2026年第一季度运营活动净现金使用170万美元，略高于2025年同期的160万美元 - **现金及现金等价物**：季度末余额为95.1万美元 ## 2. 财务指标变化：- **研发费用**：同比下降29.5万美元至120万美元（2025年第一季度为150万美元
05-19 12:17
